You are here

Concentration Method for Thermally Labile Pharmaceutical

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 9R44GM068419-02
Agency Tracking Number: GM068419
Amount: $0.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
325 WATER STREET
WILMINGTON, DE 18904
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN BOWSER
 (302) 999-7996
 john.bowser@compactmembrane.com
Business Contact
 STUART NEMSER
Phone: (302) 999-7996
Email: SNEMSER@COMPACTMEMBRANE.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Freeze-drying is commonly employed to concentrate temperature-sensitive pharmaceuticals. Freeze-drying is expensive and causes product degradation. Osmotic distillation (OD) is a candidate for gentler and lower-cost concentration but has not been commercially developed because microporous membranes fail due to wet-out. In Phase I, Compact Membrane Systems (CMS) used novel membranes to concentrate a model enzyme without wetting-out or causing activity loss as compared to control. Working with an industrial pharmaceutical company, we used OD to concentrate an antibiotic prior to super critical fluid extraction (SCFE). The OD-SCFE method recovered 27% more antibiotic than the traditional chemical extraction method. We have gained support from an industrial pharmaceutical company and two major membrane companies. These relationships enhance CMS's ability to complete Phase II and commercialize this technology. In Phase II, we will collaborate with our pharmaceutical partner to develop a process using OD for initial dewatering and SCFE for final concentration. Our Phase II focus will be: a) Further developing membrane/module for OD of pharmaceutical products b) Working with our pharmaceutical partner to build and test prototype system c) Obtaining key basic data and performing economic analysis
d) Performing long-term stability testing of OD process and biopharmaceutical product.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government